20
Participants
Start Date
March 3, 1999
Primary Completion Date
April 20, 2001
Study Completion Date
October 19, 2001
rV-DF3/MUC1
"\- The starting dose for this Phase I study of rV-DF3/MUC1 will be 4.76 x 106 PFU.~\-- Dose escalation will proceed with cohorts of at least 6 patients as follows: Per vaccination~* Level 1 4.76 x 106 PFU~* Level 2 4.76 x 107 PFU~* Level 3 4.76 x 108 PFU"
Massachusetts General Hospital Cancer Center, Boston
Brigham and Women's Hospital, Boston
Dana-Farber Cancer Institute, Boston
Boston Medical Center, Boston
National Cancer Institute (NCI)
NIH
Dana-Farber Cancer Institute
OTHER